A Phase III Randomised Controlled Trial Evaluating the Malaria Vaccine Candidate R21/Matrix-M™ in African Children
Mehreen Datoo(University of Oxford), Adrian V. S. Hill(Jenner Institute), Alassane Dicko(Ministère de la Santé et de l'Hygiène Publique), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Fernando Ramos Lopez(University of Oxford), Ally Olotu(Ifakara Health Institute), Emma Beaumont(London School of Hygiene & Tropical Medicine), Djibrilla Issiaka, Yves Daniel Compaoré, Sophie Weston(University of Oxford), Mainga Hamaluba(Universidade Federal do Rio Grande do Sul), Hamtandi Magloire Natama(Centre National de la Recherche Scientifique et Technologique), Mwajuma Chemba(Ifakara Health Institute), Diallo Salou(Institut de Recherche en Sciences de la Santé), Sharon Omenda(Kenya Medical Research Institute), Jean‐Bosco Ouédraogo(Institut de Recherche en Sciences de la Santé), Alison Lawrie, Philip Bejon(Nuffield Orthopaedic Centre)
Cited by 29
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451